Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Heart shield? common diabetes drug tested to prevent Chemo-Induced heart damage

NCT ID NCT07070765

First seen May 13, 2026 · Last updated May 23, 2026 · Updated 3 times

Summary

This study tests whether a daily pill called dapagliflozin (a diabetes drug) can prevent heart damage in breast cancer patients receiving anthracycline chemotherapy. About 70 women aged 18-70 with low to medium heart risk will take the drug during their chemo. The goal is to see if it keeps the heart's energy levels healthy and reduces the chance of long-term heart problems.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cardiac Research Office, Aberdeen Royal Infirmary

    RECRUITING

    Aberdeen, Aberdeenshire, AB25 2ZD, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Aberdeen

    RECRUITING

    Aberdeen, AB25 2ZD, United Kingdom

    Contact Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.